SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in popularity as the community rallies around its status as a long-standing parody of Bitcoin, with users debating whether its satirical roots give it staying power as a legitimate asset. Supporters are actively pointing to its unique lore, growing holder count, and high-profile endorsements as catalysts, while others remain skeptical, fueling a polarized discussion about its long-term potential in the meme coin space.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The community is rallying behind the multichain meme project crow with knife, highlighting its deflationary burn mechanism and organic growth as primary drivers of their bullish sentiment. Discussions are dominated by high-energy engagement and a strong conviction that the token serves as a unique asset within the current meme coin landscape.

Maulcoin

Maulcoin is trending as its community aggressively pushes for a break into 'penny land,' fueled by excitement over potential airdrops and expectations of an upcoming chart listing. Supporters are actively rallying on social media to build momentum, framing the project as a long-term, community-driven alternative to typical meme coin pump-and-dump schemes.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as institutional investors debate whether the sector's aggressive AI-driven rally is facing a distribution phase or a continuation setup. The community is heavily focused on the disconnect between soaring AI infrastructure capex and mounting concerns over data center cancellations, power grid constraints, and valuation premiums.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors aggressively build positions in anticipation of a transformative FDA Biologics License Application decision and pivotal clinical data readouts expected in the coming year. The community remains highly focused on the competitive potential of ivonescimab against existing immunotherapies, with intense debate ongoing regarding its high short interest and the strategic maneuvering of management ahead of key industry conferences.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Telix Pharmaceuticals Ltd. - ADR

Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals is gaining significant investor attention following the FDA's acceptance of its NDA for its brain cancer imaging agent, with the community closely tracking upcoming regulatory milestones and board appointments that signal potential for long-term growth. Traders are actively debating the company's competitive position in the radiopharmaceutical sector and its ability to scale its commercial infrastructure alongside a promising late-stage pipeline.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently trending as investors weigh strong production performance and ongoing cost-synergy gains from the Marathon Oil acquisition against broader industry concerns over softening oil prices. The community is actively discussing the stock's resilience and dividend sustainability while monitoring how geopolitical tensions might influence future energy supply dynamics.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is seeing heightened community discussion as investors monitor potential ETF developments and look for signs of a broader market reversal alongside Bitcoin. While some retail participants remain cautious due to market volatility and ongoing debates over memecoin utility, others are actively accumulating tokens in anticipation of a recovery trend.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as a leading proxy for SpaceX, driven by investor optimism surrounding a potential high-valuation IPO and the company's significant equity stake acquired through recent spectrum deals. Market participants are actively debating the company's valuation metrics and the potential for a short squeeze, positioning the stock as a high-beta setup tied to the upcoming space sector catalysts.

TON (The Open Network) is a general-purpose&nbsp;blockchain that allows developers to build decentralized apps and tokens.

Toncoin

Toncoin is capturing market attention as its integration with Telegram reaches a massive user base, with traders highlighting recent sub-second network upgrades and high APY staking opportunities. Community discussion is currently centered on increased institutional adoption, including new ETP listings and strategic whale accumulation despite recent price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) has received a consensus rating of "Hold" from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a b...

HC Wainwright Issues Positive Outlook for INKT Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Equities researchers at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a note issued to investors on Wednesday, April 1st. HC Wainwright analyst E. Bodnar now expects that the company will po...

MiNK Therapeutics Q4 Earnings Call Highlights

MiNK Therapeutics (NASDAQ:INKT) outlined progress across its allogeneic invariant natural killer T-cell (iNKT) platform during its fourth quarter and year-end 2025 financial results conference call, highlighting updated clinical observations in solid tumors, plans to initiate randomized testing in s...

MiNK Therapeutics (NASDAQ:INKT) Director Barbara Ryan Sells 1,300 Shares

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) Director Barbara Ryan sold 1,300 shares of MiNK Therapeutics stock in a transaction that occurred on Tuesday, March 10th. The shares were sold...

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

MiNK Therapeutics stock drops after a 30% rally as investors react to profit taking and a $1.1 million pediatric cancer therapy deal.read more...

Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare

Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW

MiNK Therapeutics Pediatric Cancer Breakthrough Sparks Stock Rally

MiNK Therapeutics' stock rises premarket after announcing a pediatric cancer cell therapy collaboration with C-Further and $1.1 million funding.read more...

<ul class="summary-bullets"><li>The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T cell therapy to treat pediatric tumors.</li><li>The program will receive around $1.1 million in funding to support its early-stage development.</li><li>The agreement provides for a double-digit share of future commercial revenues.</li></ul>Shares of MiNK Therapeutics (INKT) gave up most of their early gains to trade 32% higher on Tuesday after the company announced a collaboration with the C-Further, an oncology consortium, to develop a cell therapy targeting pediatric cancers.The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy to treat pediatric tumors. Preferentially Expressed Antigen in Melanoma, or PRAME, is a tumor antigen found in several cancers.MiNK’s iNKT platform aims to address key limitations of traditional cell therapies, which require patient-specific manufacturing and long preparation times.&nbsp;The therapy is derived from healthy donors and can be produced in advance, stored, and delivered when needed without complex matching or intensive pre-treatment. This approach could allow faster treatment and broader access, especially for children with aggressive cancers, the company said.&nbsp;<h2 class="st-heading-2">Program To Receive $1.1 Million In Funding</h2>By combining PRAME-targeting with MiNK’s iNKT cell platform, the therapy aims to precisely attack tumors while also activating broader immune responses.The program will receive around $1.1 million in funding to support its early-stage development, and the agreement also provides for a double-digit share of future commercial revenues, the company added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for <a href="https://stocktwits.com/Breakoutstockmoves/message/647092507">INKT</a> on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/INKT_jpg_8148d6ae77.webp" alt="INKT.jpg">One user saw support at $13.5.<stembedurl>https://stocktwits.com/cjwaters14/message/647135253</stembedurl>Another user said the $1 million funding was a "small teaser" ahead of a potential buyout.<stembedurl>https://stocktwits.com/Breakoutstockmoves/message/647092507</stembedurl>Year-to-date, the stock gained 24%.For updates and corrections, email newsroom[at]stocktwits[dot]com

Representative image of a trending stock chart.

Why Did INKT Stock Jump 30% Today?

MiNK Therapeutics tied up with an oncology consortium to develop a cell therapy targeting pediatric cancers.

Equity

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Rating of "Hold" from Brokerages

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have received an average recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Consensus Recommendation of "Hold" from Analysts

Shares of MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) have been given an average rating of "Hold" by the five research firms that are currently covering the company, MarketBeat Ratings...

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Current Price	$11.04
Prev Close	$11.47
Open	$11.49
Dividend Yield	0.00%
50-Day Moving Average	$10.78
Beta	0.62
Avg. Volume	796,738.76
PE Ratio	-3.72

52-Week High	$76.00
52-Week Low	$6.34
Market Capitalization	$54.82M
EPS (Annual)	-$2.93
Price to Book	-3.65
Revenue Per Employee	$0.00

INKT
MiNK Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INKT News

INKTMiNK Therapeutics Inc